May 9 (Reuters) - Endo International Plc reported a 7.7 percent rise in quarterly revenue, helped by strong demand for its newly launched generic drugs.
However, the drugmaker’s net loss attributable to shareholders widened to $173.8 million, or 78 cents per share, in the first quarter ended March 31 from $133.9 million, or 60 cents per share, a year earlier.
The company booked an asset impairment charge of $204 million in the latest quarter.
Total revenue rose to $1.04 billion from $963.5 million. (Reporting by Divya Grover in Bengaluru; Editing by Anil D‘Silva)